Inhalation And Nasal Spray Generic Drugs Market Size & Trend Report, 2022-2030
The global Inhalation And Nasal Spray Generic Drugs market size was estimated at USD 17.51 billion in 2021 and is expected to surpass around USD 38.45 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 8.98% during the forecast period 2022 to 2030.
Key Takeaways:
The market is primarily driven by the rising incidence of chronic respiratory diseases globally. According to the Global Asthma Report, nearly 330 million people have asthma worldwide and this number is expected to reach more than 400 million cases by 2025. Increasing tobacco use, air pollution, and smoking are some of the major causes leading to rising asthma cases globally.
Increasing geriatric population, coupled with its increased susceptibility to chronic respiratory diseases, is expected to drive the market. As per the WHO estimates, 1 out of 6 people will be aged 6o years and above worldwide by 2030. Furthermore, the world population of such individuals is estimated to reach 2.1 billion by 2050. Moreover, the Asthma & Allergy Foundation of America states that about 7.8% of the U.S. population aged 65 and older had asthma in 2020.
Key players such as Cipla Inc.; Teva Pharaceuticals; and Viatris Inc. are focusing on new product developments and launches. Increasing number of generic inhalation and nasal spray product approvals for the treatment of respiratory diseases including asthma, COPD, and allergic rhinitis is anticipated to fuel market growth. For instance, in March 2022, Mylan Pharmaceuticals, a Viatris Inc. subsidiary, received FDA approval for ANDA for inhalation aerosol Breyna, a generic version of Symbicort indicated for asthma and COPD patients. This approval supports the company’s objective of launching Breyna in 2022.
However, the regulatory obstructions due to stringent laws for the sales of generic drugs in countries such as Mexico and Russia are expected to hamper the market growth. For instance, COFEPRIS, the regulatory authority of Mexico, announces new guidelines for granting registrations of generic drugs, which will not include patents of new therapeutic uses in its linkage system. Furthermore, COFEPRIS exercises a special procedure window for generic pharmaceutical products in Mexico.
Report Scope of the Inhalation And Nasal Spray Generic Drugs Market
|
Report Coverage |
Details |
|
Market Size |
US$ 38.45 Billion by 2030 |
|
Growth Rate |
CAGR of 8.98% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Drug class; indication; patient demographics; end-user; distribution channel and Region, |
|
Companies Mentioned |
Teva Pharmaceuticals Industries Ltd.; Mylan N.V.; Akorn Operating Company LLC; Cipla Inc.; Sandoz International GmbH (Novartis AG); Apotex Inc.; Hikma Pharmaceuticals PLC; Sun Pharmaceuticals Industries Ltd.; Beximco Pharmaceuticals Ltd.; Nephron Pharmaceuticals Corporation |
Drug Class Insights
The bronchodilators segment accounted for the largest revenue share of over 25.2% in 2021 owing to its high adoption for the treatment of respiratory diseases including asthma and COPD worldwide. The rising prevalence of asthma and COPD is further driving the segment. As stated by the WHO, in 2019, around 262 million people were suffering from asthma. Also, according to the Asthma and Allergy Foundation of America, in 2020, 1 in every 13 people, which is nearly 25 million U.S. people, had asthma. Thus, rise in the use of bronchodilators is expected to drive the market.
The combination drugs segment is expected to expand at the fastest CAGR of 9.85% during the forecast period. This growth is attributed to the launch of combination drugs by key players including Apotex Inc. and Teva Pharmaceutical Industries Ltd. For instance, in March 2020, Apotex Inc. launched a generic version of Meda Pharmaceuticals’ Dymista (a combination drug of azelastine and fluticasone) nasal spray used for the treatment of allergic rhinitis.
Patient Demographics Insights
The adult patient segment accounted for the largest revenue share of over 40.3% in 2021. Rising number of adult patients suffering from asthma and COPD is the major factor contributing to the segment growth. According to the CDC, among total asthmatic patients, around 60% are aged between 18 and 65. Also, according to the European Respiratory Society, females are more likely to develop asthma throughout their lifetime than males. Moreover, asthma is almost twice as prevalent in females aged 18 and above than adult males. According to the CDC, nearly 13.5 million women were affected with asthma in comparison to 7.4 million men in the U.S. in 2020.
The pediatric patient segment is expected to grow during the forecast period owing to the rising use of inhalers for the treatment of cystic fibrosis, asthma, and chronic lung disease in children. Rising government initiatives for childhood asthma awareness programs boost the adoption of inhalers. For instance, the National Childhood Asthma Media Campaign is designed in association with the Ad Council to increase awareness regarding the prevention and management of asthma.
End-user Insights
The homecare segment accounted for the largest revenue share of over 50.2% in 2021 owing to favorable reimbursement policies and growing elderly population. Home care involves the management of respiratory disorders at the residence of patients and homecare facilities. Rising healthcare awareness and product advancement allow patients to use inhalers and nasal sprays at home without the assistance of medical professionals. Also, increasing geriatric population further boosts the segment growth. According to the WHO, 1 billion were aged 60 years and more in 2020 and this number will increase to 1.4 billion by 2030 and 2.1 billion by 2050, worldwide.
The homecare segment is expected to expand at the fastest CAGR during the forecast period. Rising awareness regarding the management and prevention of asthma attacks in children and adult patients is boosting the segment growth. Also, the usage of inhalers at home for the management of asthma, COPD, and other respiratory diseases has grown significantly owing to government support, awareness programs, and rising healthcare spending. For instance, in the U.S., CDC’s National Asthma Control Program helps people with asthma to achieve a better quality of life.
Distribution Channel Insights
Retail pharmacies accounted for the largest revenue share of over 55.1% in 2021 due to increasing healthcare expenditure and high generic drug sales. For instance, in 2019, generic drugs accounted for about 90% of prescription drugs dispensed in the U.S. Moreover, on average, the gross margin of generics in pharmacies is approximately 43% indicating high revenue. In addition, overall pharmaceutical expenditure has increased through the years. For instance, the expenditure on pharmaceuticals in the U.S. grew by 4.9% from 2019 to 2020.
The online pharmacies segment is expected to grow during the forecast period. Online pharmacies offer ease of access and convenience to patients. With increase in internet penetration, the number of users purchasing online pharmacy products is increasing rapidly. For instance, in 2020, the number of products dispensed from online pharmacies increased by about 45% from the previous year in England.
Indication Insights
The asthma segment accounted for the largest revenue share of over 40.2% in 2021 owing to the increased prevalence of asthma attacks among children and adults. As per the National Health Interview Survey under the CDC, around 10.3 million children aged 18 and below and adults encountered asthma attacks in 2020 in the U.S., which accounted for 41.1% of cases. Moreover, in 2019, the rate of emergency department visits for asthma increased by nearly 57.4%.
The Chronic Obstructive Pulmonary Disease (COPD) segment is anticipated to grow during the forecast period owing to the launch of new products and rising demand for generics for the treatment of COPD. For instance, in January 2019, Mylan N.V.’s WixelaInhub, a generic counterpart of Advair Diskus, was granted FDA approval for treating COPD and asthma. Such approvals are expected to accelerate market growth.
Regional Insights
North America dominated the market with a revenue share of over 35.0% in 2021. The launch of new products, acquisitions and partnerships, and increased prevalence of chronic respiratory diseases are the major factors fueling the regional growth. According to the CDC, the prevalence of chronic obstructive pulmonary disease (COPD) in the U.S. is 57 per 100,000 in men and 40.5 per 100,000 among women. The launch of generic versions of nasal sprays is expected to fuel market growth. For instance, in December 2021, Sandoz launched a generic form of Narcan (naloxone HCl) Nasal Spray indicated for opioid overdose reversal in the U.S.
Asia Pacific is expected to register a lucrative CAGR of 11.23% during the forecast period. The growth of the region is attributed to the strategic partnerships to manufacture generic products in the region. For instance, in August 2021, CDMO Bora Pharmaceuticals Laboratories Inc. partnered with Kyowa Pharmaceuticals Industry Co. Ltd. to manufacture generic products, including nasal sprays, in Japan. This contract strengthens and increased visibility of Taiwan’s pharmaceutical capabilities.
Some of the prominent players in the Inhalation And Nasal Spray Generic Drugs Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Inhalation And Nasal Spray Generic Drugs market
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Inhalation And Nasal Spray Generic Drugs Market Study:
Chapter 1 Methodology and Scope
1.1 Market segmentation
1.1.1 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 Nova one advisor internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.3.6 List of primary sources
1.4 Information or data analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity flow analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Abbreviations
1.11 Objectives
1.11.1 Objective 1
1.11.2 Objective 2
1.11.3 Objective 3
1.11.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Regulatory framework
3.3 Penetration and Growth Prospect Mapping
3.4 Pipeline Analysis
3.5 Market Dynamics
3.5.1 Market driver analysis
3.5.2 Market restraint analysis
3.6 PESTEL Analysis
Chapter 4 Global Inhalation & Nasal Spray Generic Drugs Market - Segment Analysis, By Drug Class, 2018 - 2030
4.1 Global Inhalation & Nasal Spray Generic Drugs Market: Drug Class Movement Analysis
4.2 Bronchodilators
4.2.1 Bronchodilators market estimates and forecast, 2018 - 2030
4.3 Combination Drugs
4.3.1 Combination drugs market estimates and forecast, 2018 - 2030
4.4 Corticosteroids
4.4.1 Corticosteroids market estimates and forecast, 2018 - 2030
4.5 Decongestant Sprays
4.5.1 Decongestant sprays market estimates and forecast, 2018 - 2030
4.6 Antihistamines
4.6.1 Antihistamines market estimates and forecast, 2018 - 2030
4.7 Others
4.7.1 Others market estimates and forecast, 2018 - 2030
Chapter 5 Global Inhalation & Nasal Spray Generic Drugs Market - Segment Analysis, by Indication, 2018 - 2030
5.1 Global Inhalation & Nasal Spray Generic Drugs Market: Indication Movement Analysis
5.2 Asthma
5.2.1 Asthma market estimates and forecast, 2018 - 2030
5.3 Chronic Obstructive Pulmonary Disease (COPD)
5.3.1 Chronic obstructive pulmonary disease market estimates and forecast, 2018 - 2030
5.4 Allergic Rhinitis
5.4.1 Allergic rhinitis market estimates and forecast, 2018 - 2030
5.5 Others
5.5. 1 Others market estimates and forecast, 2018 - 2030
Chapter 6 Global Inhalation & Nasal Spray Generic Drugs Market - Segment Analysis, By Patient Demographics, 2018 - 2030
6.1 Global Inhalation & Nasal Spray Generic Drugs Market: Patient Demographics Movement Analysis
6.2 Adult Patient
6.2.1 Adult patient market estimates and forecast, 2018 - 2030
6.3 Pediatric Patient
6.3.1 Pediatric patient market estimates and forecast, 2018 - 2030
6.4 Geriatric Patient
6.4.1 Geriatric patient market estimates and forecast, 2018 - 2030
Chapter 7 Global Inhalation & Nasal Spray Generic Drugs Market - Segment Analysis, By End-User, 2018 - 2030
7.1 Global Inhalation & Nasal Spray Generic Drugs Market: End-user Movement Analysis
7.2 Hospitals
7.2.1 Hospital market estimates and forecast, 2018 - 2030
7.3 Cancer Institutes
7.3.1 Cancer Institutes market estimates and forecast, 2018 - 2030
7.4 Others
7.4.1 Others market estimates and forecast, 2018 - 2030
Chapter 8 Global Inhalation & Nasal Spray Generic Drugs Market - Segment Analysis, By Distribution Channel, 2018 - 2030
8.1 Global Inhalation & Nasal Spray Generic Drugs Market: Distribution ChannelMovement Analysis
8.2 Retail Pharmacies
8.2.1 Retail pharmacies market estimates and forecast, 2018 - 2030
8.3 Hospitals Pharmacies
8.3.1 Hospitals pharmacies market estimates and forecast, 2018 - 2030
8.4 Online Pharmacies
8.4.1 Online pharmacies market estimates and forecast, 2018 - 2030
Chapter 9 Inhalation & Nasal Spray Generic Drugs Market: Segment Analysis, by Region, 2018 - 2030
9.1 Inhalation & Nasal Spray Generic Drugs Market: Regional Movement Analysis
9.1.1 North America
9.1.1.1 North America market estimates and forecast, 2018 - 2030
9.1.1.2 U.S.
9.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030
9.1.1.3 Canada
9.1.1.3.1 Canada market estimates and forecast, 2018 - 2030
9.1.2 Europe
9.1.2.1 Europe market estimates and forecast, 2018 - 2030
9.1.2.2 U.K.
9.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030
9.1.2.3 Germany
9.1.2.3.1 Germany market estimates and forecast, 2018 - 2030
9.1.2.4 France
9.1.2.4.1 France market estimates and forecast, 2018 - 2030
9.1.2.5 Spain
9.1.2.5.1 Spain market estimates and forecast, 2018 - 2030
9.1.2.6 Italy
9.1.2.6.1 Italy market estimates and forecast, 2018 - 2030
9.1.2.7 Russia
9.1.2.7.1 Russia market estimates and forecast, 2018 - 2030
9.1.3 Asia Pacific
9.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030
9.1.3.2 Japan
9.1.3.2.1 Japan market estimates and forecast, 2018 - 2030
9.1.3.3 China
9.1.3.3.1 China market estimates and forecast, 2018 - 2030
9.1.3.4 India
9.1.3.4.1 India market estimates and forecast, 2018 - 2030
9.1.3.5 Australia
9.1.3.5.1 Australia market estimates and forecast, 2018 - 2030
9.1.3.6 South Korea
9.1.3.6.1 South Korea market estimates and forecast, 2018 - 2030
9.1.3.7 Singapore
9.1.3.7.1 Singapore market estimates and forecast, 2018 - 2030
9.1.4 Latin America
9.1.4.1 Latin America market estimates and forecast, 2018 - 2030
9.1.4.2 Brazil
9.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030
9.1.4.3 Mexico
9.1.4.3.1 Mexico market estimates and forecast, 2018 - 2030
9.1.4.4 Argentina
9.1.4.4.1 Argentina market estimates and forecast, 2018 - 2030
9.1.5 Middle East & Africa
9.1.5.1 Middle East & Africa market estimates and forecast, 2018 - 2030
9.1.5.2 South Africa
9.1.5.2.1 South Africa market estimates and forecast, 2018 - 2030
9.1.5.3 Saudi Arabia
9.1.5.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030
9.1.5.4 United Arab Emirates
9.1.5.4.1 United Arab Emirates market estimates and forecast, 2018 - 2030
Chapter 10 Global Inhalation & Nasal Spray Generic Drugs Market: Competitive Analysis
10.1 Recent Developments and Impact Analysis, by Key Market Participants
10.1.1 Major deals & strategic alliances analysis
10.1.1.1 New Product Launches
10.1.1.2 Mergers and Acquisitions
10.1.1.3 Partnerships & Agreements
10.2 Company Categorization
10.2.1 Innovators
10.2.2 Market Leaders
10.2.3 Emerging Players
10.2.4 Heat Map Analysis
10.3 Company Market Position Analysis
10.4 Vendor Landscape
10.4.1 List of Key Distributors and Channel Partners
10.4.2 List of Potential End Users
10.4.3 Key Company Market Share Analysis, 2021
10.5 Company Market Share, 2021
10.5.1 Competitive Dashboard Analysis
10.6 Private Companies
10.6.1 List of Key Emerging Companies
10.6.2 Regional Network Map
10.7 Company Profiles
10.7.1 Teva Pharmaceuticals
10.7.1.1 Company overview
10.7.1.2 Financial performance
10.7.1.3 Product benchmarking
10.7.1.4 Strategic initiatives
10.7.2 Viatris Inc.
10.7.2.1 Company overview
10.7.2.2 Financial performance
10.7.2.3 Product benchmarking
10.7.2.4 Strategic initiatives
10.7.3 Akorn, Inc.
10.7.3.1 Company overview
10.7.3.2 Financial performance
10.7.3.3 Product benchmarking
10.7.3.4 Strategic initiatives
10.7.4 Cipla Inc.
10.7.4.1 Company overview
10.7.4.2 Financial performance
10.7.4.3 Product benchmarking
10.7.4.4 Strategic initiatives
10.7.5 Sandoz (Novartis AG)
10.7.5.1 Company overview
10.7.5.2 Financial performance
10.7.5.3 Product benchmarking
10.7.5.4 Strategic initiatives
10.7.6 Apotex Inc.
10.7.6.1 Company overview
10.7.6.2 Product benchmarking
10.7.6.3 Strategic initiatives
10.7.7 Hikma Pharmaceuticals PLC
10.7.7.1 Company overview
10.7.7.2 Financial performance
10.7.7.3 Product benchmarking
10.7.8 Sun Pharma
10.7.10.1 Company overview
10.7.10.2 Financial performance
10.7.10.3 Product benchmarking
10.7.10.4 Strategic initiatives
10.7.9 Beximco Pharmaceuticals Limited
10.7.9.1 Company overview
10.7.9.2 Financial performance
10.7.9.3 Product benchmarking
10.7.9.4 Strategic initiatives
10.7.10 Nephron Pharma
10.7.10.1 Company overview
10.7.10.2 Financial performance
10.7.10.3 Product benchmarking
10.7.10.4 Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers